Soleno Therapeutics (SLNO) Gross Margin (2015 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Gross Margin of 98.73% for Q1 2026, little changed quarter-over-quarter from 99.06% in Q4 2025.
Soleno Therapeutics (SLNO) Gross Margin (2015 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Gross Margin for 5 consecutive years, with 98.73% the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Margin changed N/A year-over-year to 98.73%; the TTM figure through Mar 2026 stood at 98.63% (changed N/A YoY), while the FY2025 annual figure was 98.58%, changed N/A from the prior year.
- Gross Margin steadied at 98.73% in Q1 2026 per SLNO's latest filing, from 99.06% in the prior quarter.
- Across five years, Gross Margin topped out at 99.06% in Q4 2025 and bottomed at 97.87% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 98.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 98.73% |
| Dec 31, 2025 | 99.06% |
| Sep 30, 2025 | 98.27% |
| Jun 30, 2025 | 97.87% |
| Jun 30, 2017 | -4,100.00% |
| Mar 31, 2017 | 21.13% |
| Dec 31, 2016 | 4.24% |
| Sep 30, 2016 | -21.28% |
| Jun 30, 2016 | -2,450.00% |
| Mar 31, 2016 | -3.13% |
| Dec 31, 2015 | -3.93% |
| Sep 30, 2015 | 77.33% |
| Jun 30, 2015 | 77.32% |
| Mar 31, 2015 | 18.18% |